1 t patients (N = 180) were assigned to 1 of
3 LAAM doses.
2 e long-acting opiate l-alpha-
acetylmethadol (
LAAM), adult male and female rats were assessed for thei
3 xposed to the opiate l-alpha-
acetylmethadol (
LAAM).
4 n, while methadone, l-alpha-
acetylmethadone (
LAAM), morphine, meperidine, DADL, beta-endorphin(1-31),
5 methadone derivative l-alpha-
acetylmethydol (
LAAM) in rats.
6 Data for methadone
and LAAM suggest possible contribution from their enhanced d
7 nd phosphorylation mediated by methadone
and LAAM were disproportionate to their efficacies in two di
8 At 5-6 months, prenatal water-
and LAAM-exposed males (n=6 each; non-littermates) received
9 Levomethadyl acetate hydrochloride (known
as LAAM) is a mu-opioid agonist approved for the treatment
10 Clinical trials
comparing LAAM and methadone have reported lower patient retention
11 Female rats received 1.0 mg/kg/
day LAAM or water via daily oral gavage for 28 days prior to
12 is study compared induction with 3
different LAAM dosage levels.
13 eported lower patient retention rates
during LAAM induction; however, this may reflect dose and sched
14 Few studies have systematically
examined LAAM dose induction.
15 Induction with
higher LAAM doses can be safely achieved within 17 days, but ma
16 Induction with low and
medium LAAM doses can be safely and effectively achieved within
17 ential of nor-Levo-alpha-acetylmethadol (
nor-
LAAM) to treat OUD.
18 ghts into further developing long-acting
nor-
LAAM-MP for treating OUD.
19 of nor-LAAM-MP (F4) provided detectable
nor-
LAAM levels in rabbit plasma for at least 15 days.
20 The lead
nor-
LAAM-MP (F4) had a relatively high drug loading (11 wt%)
21 er evaluated the therapeutic efficacy of
nor-
LAAM-MP (F4) in a well-established fentanyl-addiction ra
22 A single subcutaneous injection of
nor-
LAAM-MP (F4) provided detectable nor-LAAM levels in rabb
23 We developed sustained release
nor-
LAAM-loaded poly (lactic-co-glycolic acid) (PLGA) microp
24 The
nor-
LAAM-MP prepared using HIP with pamoic acid had high dru
25 The
nor-
LAAM-MP was further optimized for desirable particle siz
26 The clinical efficacy
of LAAM is positively related to dose.
27 Thrice-weekly (Monday/Wednesday/Friday)
oral LAAM dose conditions of 25/25/35 mg, 50/50/70 mg, and 10
28 Overall,
LAAM doses were well tolerated by most patients.
29 Prenatal LAAM exposure resulted in a blunted fever response to LP
30 lating IL-1beta was not affected by
prenatal LAAM exposure, nor was IL-1beta protein in the spleen.
31 in the synaptic fraction of trained
prenatal LAAM-treated rats compared to prenatal water-treated tra
32 s elevated in the hypothalamus of
prenatally LAAM-treated rats.
33 Rats prenatally exposed
to LAAM had poorer maze performance, decreased percent corr
34 Opioid substitution treatment
with LAAM substantially reduces illicit opioid use.